The lancet. Diabetes & endocrinology
-
Lancet Diabetes Endocrinol · Apr 2016
Randomized Controlled Trial Multicenter StudyRamipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.
Angiotensin-converting enzyme inhibitors have been shown to reduce the risk of end-stage renal disease and death in non-transplant patients with proteinuria. We examined whether ramipril would have a similar beneficial effect on important clinical outcomes in kidney transplant recipients with proteinuria. ⋯ Canadian Institutes of Health Research.
-
Lancet Diabetes Endocrinol · Apr 2016
Randomized Controlled Trial Multicenter StudyRenal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.
The primary results of the ALTITUDE trial showed no benefit of aliskiren on renal outcomes (doubling of serum creatinine and end-stage renal disease) when used as an adjunct to angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) in patients with type 2 diabetes and chronic kidney disease or cardiovascular disease. We did a prespecified analysis of the ALTITUDE trial to analyse the effects of aliskiren on surrogate renal outcomes in all patients and on primary renal outcomes in subgroups of patients. ⋯ Novartis.
-
Lancet Diabetes Endocrinol · Apr 2016
Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis.
Increased circulating plasma urate concentration is associated with an increased risk of coronary heart disease, but the extent of any causative effect of urate on risk of coronary heart disease is still unclear. In this study, we aimed to clarify any causal role of urate on coronary heart disease risk using Mendelian randomisation analysis. ⋯ UK National Institute for Health Research, British Heart Foundation, and UK Medical Research Council.